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Proteinuria is the hallmark of diabetic kidney disease (DKD)
and is an independent risk factor for both renal disease
progression, and cardiovascular disease. Although the
characteristic pathological changes in DKD include
thickening of the glomerular basement membrane and
mesangial expansion, these changes per se do not readily
explain how patients develop proteinuria. Recent advances in
podocyte and glomerular endothelial cell biology have
shifted our focus to also include these cells of the glomerular
filtration barrier in the development of proteinuria in DKD.
This review describes the pathophysiological mechanisms at
a cellular level which explain why patients with DKD develop
proteinuria.
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Diabetic kidney disease (DKD) is the leading cause of chronic
and end-stage kidney disease, and is epidemic worldwide.
The clinical signature of DKD is proteinuria, which is a
marker of disease severity and is used clinically to guide our
therapies. It is also an independent risk factor for
cardiovascular disease.1,2 Proteinuria is considered to play a
central role in the pathogenesis of progressive renal
dysfunction. Mechanisms may include enhanced tubular cell
uptake of protein leading to complement activation and
tubulointerstitial inflammation and increased filtration of
pro-oxidant heme proteins, fibrogenic growth factors, and
inflammatory cytokines (reviewed in Abbate et al.).3 How-
ever, it should be recognized that progressive renal impair-
ment has recently been described in patients with diabetes in
the absence of proteinuria, despite having the classic
histological features of DKD.4 Additionally, studies have
detected a linear decline in renal function prior to the
development of overt proteinuria, questioning whether the
loss of glomerular filtration rate (GFR) is etiologically linked
to proteinuria or whether the two may occur in parallel.5
There has been an exciting increase in our understanding
of the mechanisms underlying proteinuria at a molecular and
cellular level. Although the exact chronological sequence of
events leading to the functional and histological character-
istics of DKD is not well defined, our review is based on a
model in which proteinuria is a double-edged sword: it serves
as a clinical indicator/marker of injury to the kidney, yet also
plays an integral role in the pathogenesis of DKD (see
Figure 1). In this review, we will not discuss the clinical
significance of proteinuria, the risk factors leading to DKD,
nor the treatment of proteinuria and disease progression, as
these have been keenly discussed in excellent reviews
elsewhere.3,6,7 For the most part, we will also not discuss
the pathobiology leading to the individual cellular changes,
which are highlighted in Table 1 and reviewed elsewhere.8,9
The intent of this review is to rather focus comprehensively
on the underlying mechanisms of proteinuria in DKD and to
highlight the major advances in this area.
Proteinuria and albuminuria, not microalbuminuria
Although approximately 20% (180 l) of renal plasma flow is
filtered at the glomerulus daily, only small amounts of
protein are detected in normal urine (40–80 mg day1).
Transient increases in proteinuria may occur with fever,
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marked exercise or exacerbations of congestive heart failure,
or hypertension. Urine protein typically comprises albumin
(30–40%), Tamm–Horsfall protein (50%), immunoglobulins
(5–10%), and light chains (5%). Any protein filtered at the
glomerulus is typically taken up by, and degraded in,
proximal tubular cells, then reabsorbed into peritubular
capillaries. However, peptide fragments are present in human
urine (2–3 g day1), that are not detected by standard protein
assays.10,11 Patterns of urine protein fragmentation have been
investigated and may correlate with specific glomerular
diseases.12
The term ‘microalbuminuria’ is widely used to denote
low-grade albuminuria (30–300 mg day1) and identifies
those at risk of DKD, and those at risk of cardiovascular
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Figure 1 | Proposed schema unifying the mechanisms of proteinuria and decrease in GFR in DKD. This schema summarizes events
leading to albuminuria/proteinuria (represented by the green arrows) and reduced GFR (represented by the purple arrows) in patients with
DKD. The diabetic milieu has effects on all cell types within the kidney (represented by the thick arrows) and these contribute either
primarily or secondarily to the development of albuminuria/proteinuria and reduced GFR. At the level of the glomerulus, both
hemodynamic effects and injury to the individual components of the glomerular filtration barrier (podocyte, GBM, and glomerular
endothelial cell) primarily lead to proteinuria (green arrows). In addition, tubulointerstitial injury may diminish tubular protein reuptake.
Mesangial cell injury likely contributes secondarily to proteinuria by (i) mesangial expansion causing a loss of glomerular filtration surface
area leading to glomerular hyperfiltration (dashed green arrows) or (ii) by mesangiolysis leading to structural changes in the capillary loops.
Proteinuria itself may result in a decrease in GFR by causing tubulointerstitial injury.
Table 1 | Mechanisms of proteinuria in DKD
Site of injury Effect Underlying mechanisms
Glomerular hemodynamics Glomerular hyperfiltration Afferent arteriole vasodilatation
Efferent arteriole vasoconstriction
mglomerular capillary pressure
Glomerular endothelial cell Endothelial cell injury Hyperglycemia, AGE, ROS
Diminished endothelial glycocalyx Endothelial cell injury or enzymatic cleavage
Altered VEGF signaling Podocyte injury or loss
GBM Irregular thickening kproduction and/or mdegradation of extracellular matrix proteins
Decreased negative charge k production and/or m degradation of HSPG
Podocyte Podocytopenia Detachment
Apoptosis
Lack of proliferation
Loss of slit diaphragm integrity Decrease or changes in subcellular localization of nephrin
Foot process widening and effacement Disrupted actin cytoskeleton
Loss of slit diaphragm integrity
Impaired podocyte GBM interaction
Loss negative charge kPodocalyxin
Proximal tubule Decreased protein reabsorption Tubular injury and interstitial fibrosis
AGE, advanced glycosylation end products; DKD, diabetic kidney disease; GBM, glomerular basement membrane; HSPG, heparan sulfate proteoglycan; ROS, reactive oxygen
species; VEGF, vascular endothelial growth factor.
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disease in both diabetic and nondiabetic populations.
However, it is now well recognized that, even at ‘sub-
microalbuminuric’ levels (albuminuria, 2–30 mg day1), the
risk of cardiovascular disease increases, correlating with the
degree of albumin excretion.1,2,13 In view of this, we prefer to
consider urinary albumin excretion as a continuous variable
and do not consider a specific cutoff in quantity at which the
mechanisms of albuminuria may differ. Hence, when we use
the term proteinuria, we define this as any amount of protein
in the urine (that is, micro- and macroalbuminuria).
NORMAL RENAL HANDLING OF ALBUMIN
Albumin accounts forB60% of all plasma proteins; yet only
small amounts of albumin are filtered at the glomerulus14—
although this has recently been questioned.15 Micropuncture
studies suggest a low glomerular filtrate albumin concentra-
tion (B22–32 mg l1), consistent with a glomerular filtered
albumin load of 4–5 g day1.16–18 The relative impermeability
of the glomerular capillary wall is due to both a size and
charge barrier; however, the contribution of the charge
barrier has recently been called into question.19–21
Filtered albumin is not cleaved in the tubular lumen, but
rather binds to a megalin/cubulin receptor complex in
clathrin coated pits of proximal tubular cells (predominantly
the S1 and S2 segments)16 (Figure 2a and c), where it
undergoes receptor-mediated endocytosis.22 Inhibitors of
3-hydroxy-3 methylglutaryl-CoA reductase (statins) inhibit
this endocytosis, limiting uptake and may result in
proteinuria.23 Endocytic vesicles detach from the apical
membrane and deliver the albumin–megalin–cubulin com-
plex to a sorting endosomal compartment, where the
albumin dissociates (due to the low pH), and megalin/
cubulin are recycled to plasma membrane. Albumin subse-
quently reaches the lyzosomal compartment, where it is
cleaved and the amino acids reabsorbed or peptide fragments
‘regurgitated’ into the tubular lumen.
RENAL PATHOLOGY IN DIABETIC KIDNEY DISEASE
To understand the mechanisms underlying the inability of
diabetic kidneys to prevent urinary protein leakage, we must
first identify the renal histological abnormalities in DKD
(Figure 3). Kidneys are typically enlarged as a result of
hypertrophy of tubular cells and of all the glomerular cell
types (glomerulomegaly). The characteristic histological
features on renal biopsy include thickening of the glomerular
basement membrane (GBM) and mesangial expansion
(Figure 3). GBM thickening, the earliest detectable feature,24
is due to the deposition of mostly normal GBM constituents
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Figure 2 | Normal renal handling of albumin. (a) Normal glomerulus and proximal tubule. The individual cells and constituents of the
glomerulus and proximal tubules are shown. Albumin (represented by green spheres) normally remains within the capillaries of the
glomerular tuft, and does not escape into the urinary (Bowman’s) space. (b) Glomerular filtration barrier. This barrier comprises the
innermost glomerular endothelial cells, GBM, and outermost podocytes; and serves to serially limit albumin escaping from the capillary
loops. Fenestrae within specialized endothelial cells are covered by a negatively charged glycocalyx. Podocytes attach to the outermost
aspect of the GBM by foot processes, between which are proteins comprising the size barrier slit diaphragm. (c) Proximal tubule. The
albumin that is physiologically filtered at the level of glomerulus into the urinary space is taken up by the megalin/cubulin receptor lining
the brush border of proximal tubular cells. Albumin is internalized by vesicles, and upon lysozyme action, the resultant fragments are either
reabsorbed or secreted back into the tubular lumen as albumin fragments.
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including type IV collagen a3, a4, and a5 chains, likely
produced by podocytes. Mesangial expansion is mostly
secondary to increased extracellular matrix proteins (type
IV collagen (a1 and a2 chains), type V and VI collagen,
laminins, and fibronectin), and to a lesser degree, mesangial
cell hypertrophy.25 Over time, there is disruption and
disintegration of the normal glomerular architecture due to
mesangiolysis, leading to microaneurysm formation, and the
development of the characteristic Kimmelstiel–Wilson no-
dules is seen (Figure 3c–e). The mesangial changes (increased
mesangial fractional volume) lead to a decrease in filtration
surface area and have been most closely correlated with a
reduced GFR.25 By contrast, it remains unclear, how
mesangial cell injury per se causes significant proteinuria
(see below). That GBM thickening and mesangial expansion
occur in long-term diabetes without albuminuria suggests
that these changes may not be the primary mechanisms of
proteinuria.26–29
Electron microscopy evidence for podocyte injury in DKD
includes foot process widening and effacement, and reduced
podocyte number. Glomerular endothelial cell injury is not a
prominent pathological finding in DKD, although reduced
endothelial fenestration has been described.30 Hyaline
deposits between the GBM and endothelial cell (hyaline
caps) and along the parietal surface of Bowman’s capsule
(capsular drops) may also be present. Finally, glomerular
changes of DKD are typically associated with prominent
vascular lesions (arteriosclerosis and arteriolar hyalinosis)
and tubulointerstitial injury (thickening of the tubular
basement membrane; tubular cell hypertrophy) with pro-
gressive interstitial fibrosis at later stages.
GLOMERULAR FILTRATION BARRIER: A SERIES OF RESISTORS
TO PROTEINURIA
The renal pathologic findings described above do not readily
explain proteinuria (urinary albumin excretion
430 mg day1) in DKD. Albuminuria/proteinuria results
from defects in the glomerular filtration barrier, although
abnormalities in tubular albumin reabsorption may also
contribute. The glomerular filtration barrier comprises a
series of resistors (or layers) separating the blood side
(glomerular capillary) from the urinary (Bowman’s) space.
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Figure 3 | Characteristic glomerular changes of DKD. (a) Normal glomerulus. Cells of the glomerular tuft (mesangial cells, endothelial
cells, and podocytes) and extracapillary glomerulus (parietal epithelial cells) are shown, along with the GBM. (b) Diabetic kidney. In the
diabetic kidney, characteristic glomerular changes include thickening of GBM and mesangial expansion (due to increased mesangial matrix
and increased mesangial cell size due to hypertrophy). The filtration surface is therefore reduced due to mesangial expansion, leading to
reduced glomerular filtration rate. Podocytes undergo several changes, including a reduction in cell number as illustrated. (c) Light
micrograph showing mesangial changes. Mesangiolysis leads to disruption of the normal mesangial cell architecture. The hallmark of DKD is
a localized increase in extracellular matrix proteins resembling a nodule (called Kimmelstiel–Wilson nodule). In addition, arterioles are injured
in DKD, with characteristic hyalinosis, leading to a reduction in lumen size. (d) Electron micrograph showing mesangial cell changes. A large
Kimmelstiel–Wilson nodule is shown encroaching upon the capillary lumen. The capillary architecture is normally supported by mesangial
cells. This function is disrupted due to mesangiolysis, resulting in capillary lumen expansion and the formation of microaneurysms.
(e) Electron microscope of glomerular filtration barrier in DKD. This figure shows that two layers of the filtration barrier are abnormal. The
GBM is thickened, and the shape of podocytes is abnormal (effacement). (Pathology images courtesy of Jolanta Kowalewska.)
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These include the innermost fenestrated glomerular endo-
thelium, the middle GBM, and the outermost podocyte (also
called the glomerular visceral epithelial cell) (Figure 2b).
Each layer likely contributes uniquely to the impermeability
to albumin, although recent studies suggest that the podocyte
slit diaphragm may be the predominant barrier to albumi-
nuria. Seminal dextran sieving studies by Brenner and
others31–33 suggested a size, charge, and conformational
glomerular barrier, although technical concerns regarding the
use of dextrans have led to some aspects of this model being
questioned.34 Several theoretical models of macromolecular
transport across the glomerular filtration barrier have since
been proposed. A bimodal pore-size model seems to most
accurately fit the polymer sieving data,35,36 where numerous
restrictive pores exist (diameter 37–48 A˚) whereas fewer large
pores (60–80 A˚) function as a shunt pathway. Charge and size
selectivity may be changed independently of each other
suggesting different sites or mechanisms. A gel membrane
model has also been suggested recently.18
Molecular size and sieving
There is little debate about the role of molecular size on
glomerular permeability. Low molecular weight proteins
(mwo40 kDa) are essentially freely filtered,16 whereas, high
molecular weight proteins (mw4100 kDa) are almost
completely restricted.36,37 Note that the molecular weight of
albumin is 69 kDa. In patients with diabetes and low-grade
albumin excretion (o300 mg per 24 h), no change in size
selectivity (radius of pores, spread distribution of small pores,
or magnitude of large pores) has been reported, suggesting
that alterations in the charge barrier may be responsible.38,39
As the magnitude of albuminuria increases, there is an
increase in large pores, and an increase in albumin passage
through small selective pores is described that becomes more
evident at higher degrees of proteinuria.38–40
A disputed charge barrier
The significance of a glomerular charge barrier remains
debated. This was first proposed on the basis of tracer studies
showing that anionic ferritin was restricted from entering the
GBM, whereas cationic ferritin reached the podocyte slit
diaphragm.41 Further studies showed that compared with
negatively charged or neutral dextran, positively charged
dextrans were more permeable.31,32,42 More recent studies
using charged and uncharged Ficolls have questioned the
existence of a glomerular charge barrier.19–21 The site of any
anionic charge barrier has been considered to lie within the
GBM (see below); however, anionic sites have also been
demonstrated on podocytes (podocalyxin)41,43 and the
endothelial glycocalyx.41,44
Hemodynamic factors in diabetes may cause proteinuria
independent of structural kidney damage
Proteinuria/albuminuria may be increased by Starling type
forces across the glomerular capillary due to increased renal
plasma flow and/or increased glomerular capillary hydro-
static pressure (predominantly mediated by angiotensin II).
Filtration fraction, a measure of glomerular hydraulic
pressure, is elevated in patients with albuminuria in type
I45 and II diabetes.46 Acute changes in blood pressure have
been shown to reduce albumin excretion in the short term.47
By contrast, seminal studies by Anderson, Hostetter, and
Brenner showed that chronic elevation in intraglomerular
pressure leads to progressive glomerular injury, thereby
augmenting proteinuria by further damaging the filtration
barrier.48–51
Given that we believe the majority of proteinuria in DKD
is directly due to one or more abnormalities in the layers of
the glomerular filtration barrier (Figure 2b), we will focus on
how defects in each of these constituents cause proteinuria.
THE GLOMERULAR ENDOTHELIUM: FIRST RESISTOR TO
PROTEINURIA
Structure and function of the normal glomerular
endothelium
The highly specialized glomerular endothelium lining the
glomerular capillaries differs from other endothelial beds.
First, they have characteristic fenestrations (60–100 nm in
diameter) that serve to facilitate ultrafiltration.52 Second,
they are covered by a cell surface coat called the endothelial
glycocalyx44 comprising a network of proteoglycans with
negatively charged glycosaminoglycan side chains forming an
extracellular matrix. This links to soluble plasma proteins
forming a dynamic layer that is undergoing constant
turnover. Thus, from a functional standpoint, the endothelial
fenestra may facilitate high hydraulic permeability, counter-
balanced by the overlying glycocalyx, which helps to restrict
the filtration of macromolecules. The glomerular endothe-
lium has not until recently been considered to have
prominent restrictive properties. Ferritin tracer studies have
suggested that the fenestrated endothelium is mostly porous
to proteins that tend to accumulate under the GBM.53,54
However, if the glomerular endothelium does not play a
prominent role in the filtration barrier, the issue of clogging
of the filtration barrier and the question of how large
amounts of filtered albumin are returned to the circulation
need to be answered.55
Abnormalities in the glomerular endothelium cause
proteinuria in diabetes
(i) Endothelial cell injury. Systemic endothelial dysfunction
is prominent in type I and type II diabetes,56 manifest by
increased endothelial permeability,57 impaired nitric oxide
production,58 upregulation of adhesion molecules, and the
development of a pro-thrombotic phenotype. The Steno
hypothesis considers that albuminuria in diabetes may simply
reflect the kidney manifestations of systemic endothelial
dysfunction.59 Indeed, albuminuria has been associated with
an increased systemic permeability to albumin in both type
I60 and type II diabetes.61
The mechanisms underlying systemic endothelial perme-
ability remain to be fully determined, but likely include
26 Kidney International (2008) 74, 22–36
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hyperglycemia per se, glycated hemoglobin, dyslipidemia,
inflammatory cytokines, reactive oxygen species, and activa-
tion of the renin–angiotensin system (reviewed in Rask-
Madsen and King).62 Despite this, endothelial injury is not a
prominent feature of DKD on biopsy.63
(ii) Defects in the glomerular endothelial glycocalyx. Recent
data suggest a more significant role for the overlying
endothelial cell glycocalyx in the development of protein-
uria.64–67 Enzymatic cleavage (hyaluronidase and heparanase)
of hyaluronic acid and chondroitin sulfate in mice decreases
the thickness of the negatively charged endothelial glycocalyx
and is associated with an increased fractional clearance of
albumin.68,69 Notably, the clearance of neutral Ficolls
(molecular weight similar to albumin) remained unchanged,
suggesting an alteration in the glomerular charge, not size
barrier. Preliminary studies in diabetes suggest that the
systemic (sublingual capillaries) glycocalyx volume is de-
creased in longstanding type I diabetes by 50% and is further
decreased in type I diabetics with albuminuria,70 suggesting
that hyperglycemia may increase glycocalyx permeability
independent of changes in glycocalyx volume.71 The effects of
diabetes on the glomerular glycocalyx remain unknown,
although it is tempting to speculate that similar abnormal-
ities may exist.
VEGF and angiogenesis in the development of proteinuria
in diabetic kidney disease
Recent studies have confirmed increased glomerular vascu-
larity and endothelial cell proliferation at early stages of
diabetic nephropathy.72,73 Vascular endothelial growth factor
(VEGF), a pro-angiogenic factor, is prominently produced by
podocytes.74 Although VEGF may signal within the podocyte
in an autocrine fashion (via VEGFR1),75,76 VEGF protein
primarily appears to cross the GBM and to act on glomerular
endothelial cells (via VEGFR1 and VEGFR2) to promote
endothelial cell survival and to induce the formation of
fenestra, which enhance glomerular endothelial permeability.
Studies suggest that the systemic inhibition of VEGF
may lead to proteinuria. Anti-VEGF antibody or VEGF
receptor antagonists used in cancer trials have been
associated with proteinuria.77 Soluble VEGFR1 (sFlt-1)
receptor has also been identified in patients with preeclamp-
sia and proteinuria.78 Notably, local inhibition of VEGF in
the kidney impairs the glomerular filtration barrier. Using
recombinant technology with a Cre-loxP system, Quaggin
and colleagues79 have shown that podocyte-specific VEGF-
deficient mice fail to form a glomerular barrier (absent
glomerular endothelial cells) resulting in embryonic lethality.
By contrast, loss of one VEGF-A allele leads to glomerular
endothelial cell swelling (endotheliosis), nephrotic syndrome,
and renal failure by 9–12 weeks.79 The mechanisms of
proteinuria secondary to VEGF deficiency in this model
remain unclear, although the absence of WT1, nephrin, and
VEGF suggest that podocyte loss may be significant.79 It
should be recognized that the overall regulation of VEGF
appears to be critical, as studies also suggest that increased
VEGF activity may be associated with a form of collapsing
glomerulopathy and proteinuria.79
Is there a role for VEGF in DKD?. In early stages of DKD,
VEGF expression is actually upregulated within the glomer-
ulus, specifically within the podocyte, and the VEGF receptor
is similarly induced.80 In vitro, podocyte expression of VEGF
is increased by high glucose,81 angiotensin II,82 and glycated
albumin.83 Could these elevated levels of VEGF be related to
proteinuria? Just as VEGF deficiency is biologically impor-
tant, increased VEGF activity increases endothelial perme-
ability, an effect which may be abrogated by ACE
inhibition.84 Additionally, VEGF may have autocrine effects
on podocyte function leading to proteinuria.79 Blockade of
VEGF in experimental models of DKD has been shown to
improve both the early functional changes (hyperfiltration
and albuminuria)85 and the later structural changes (GBM
thickening and mesangial expansion).86 By contrast, at later
stages of DKD, VEGF expression decreases, which has been
shown to correlate with albuminuria,87 and may be
secondary to podocyte loss.88 On the basis of available
published data, the precise role of VEGF in DKD is not
clear at this time. The authors believe that while VEGF is
likely to play a significant role in proteinuria, further
definitive studies are needed in DKD before we can draw
definitive conclusions.
THE GLOMERULAR BASEMENT MEMBRANE: A PARADOX OF
THE THICKENED, YET LEAKY SECOND RESISTOR
Because of the characteristic thickening of the GBM in DKD
(Figure 3e), early studies focused almost exclusively on this
glomerular structure to explain the proteinuria. The normal
GBM is a 300–400-nm thick gel-like structure (90% water),
which arises during development from the fusion of two
distinct basement membranes (one derived from glomerular
endothelium and other from the glomerular epithelium). It
consists predominantly of type IV collagen, laminin 521
(a5b2g1), nidogen, and heparan sulfate proteoglycans
(HSPGs).
Heparan sulfate proteoglycan and the GBM charge barrier:
challenging conventional wisdom!
A positive view of HSPG. If the GBM does constitute a
charge barrier, evidence has suggested that this may be due to
loss of heparan sulfates, the sulfated glycosaminoglycan side
chains of HSPGs. Studies supporting the hypothesis that
GBM heparan sulfate contributes to the charge selectivity of
the glomerular capillary wall include (i) administration of a
monoclonal anti-heparan sulfate antibody to rats resulted in
massive proteinuria89 (ii) removal of heparan sulfate by
enzymatic cleavage (heparanase) resulted in increased GBM
permeability,90 and (iii) a reduction in heparan sulfate
immunostaining has been described in various glomerular
diseases, which correlate with the degree of proteinuria.91,92
In DKD, a reduction in immunostaining for heparan sulfate
has been described in patients with both type I93–95 and type
II diabetes,91,92 which inversely correlates with the degree of
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proteinuria (reviewed in Raats et al.).96 Studies have also
described a reduction in the HSPG core protein agrin.97,98
Alterations in HSPG levels lead one to next ask how this
matrix constituent of the GBM is regulated? It must be
recalled that the GBM is an acellular structure, and, thus, any
changes to its structure (that is, matrix proteins) is due to
changes in the cells it supports (glomerular endothelial cells
and podocytes). The decreased HSPG expression in more
advanced disease may be due to either decreased HSPG
synthesis by the podocyte or endothelial cell or increased
degradation. Decreased heparan sulfate synthesis (by
35S-sulfate incorporation) has been described in some,99,100
but not all studies.101,102 In vitro, decreased podocyte
synthesis of the core protein agrin may be caused by both a
high ambient glucose103 and angiotensin II.104 ACE inhibi-
tion prevents HSPG loss in diabetic rats and decreases
albuminuria.100 In addition, heparan sulfate in diabetes may
be undersulfated with a reduced anionic charge.99,105
Decreased activity of glucosaminyl N-deacetylase/N-sulfo-
transferase, a key enzyme in the sulfation of heparan sulfate,
has been described in the glomeruli of STZ rats.106,107
Increased enzymatic degradation of heparan sulfate
(heparanase) has been described in type II DKD and in
STZ rats.108 High ambient glucose increases the expression of
heparanase in podocytes.109 Heparanase may be inhibited by
heparin(oids), which ameliorate proteinuria in several animal
models of proteinuria. In patients with DKD, glycosamino-
glycan therapies, including sulodexide and enoxaparin, which
can inhibit heparanase, have been shown to reduce
proteinuria and may provide a new avenue for treatment if
clinical outcome studies prove positive.110,111
A negative view of HSPG. The majority of the human
studies described above were performed in more advanced
DKD. More recent studies have shown that the development
of albuminuria in early DKD is not associated with changes
in GBM heparan sulfate expression or sulfation status.112
Notably, infusing heparanase III into rats clearly removes HS
from the GBM without the development of proteinuria113
and indeed, may even block the protein passage across
the GBM.114
It is the view of the authors that the decrease in HSPG is
likely both functional and a ‘biomarker’ of glomerular cell
injury. Although decreased HSPG appears to be a common
finding in more advanced DKD, it remains unclear if this is a
contributing factor to the development of proteinuria or a
consequence of podocyte (or endothelial cell) injury.
A conundrum: how does a thickened GBM promote
proteinuria?
As described earlier, thickening of the GBM is a hallmark of
DKD, and the degree of thickening has been shown to
correlate with proteinuria.26 The thickening is due to the
accumulation of extracellular matrix; however, GBM thick-
ening may begin as early as 2 years following the onset of
diabetes, prior to albuminuria, suggesting that this may be a
nonspecific result of hyperglycemia.25,115,116
Regardless, what contributes to the increased GBM matrix
accumulation? The likely culprit is the podocyte. Exposure of
podocytes in vitro to high glucose or angiotensin II leads to a
pro-matrix phenotype, with increased synthesis of new type
IV collagen chains.75,117 Moreover, evidence for reduced
degradation also exists in that there is decreased production
of matrix-degrading enzymes (matrix metalloproteinases),118
and/or an increase in their inhibitors (tissue inhibitors of
metalloproteinases).119 In human DKD, a reduction in
matrix degradation has been described, partly due to
decreased matrix metalloproteinases, an effect ameliorated
by ACE inhibition.120 Together, the increased production and
reduced degradation favor matrix accumulation, seen
clinically as thickened GBM. The role of the glomerular
endothelial cell, which also lines the GBM, is unclear as it is
related to the thickening process.
Finally, how could an increase in GBM thickness result in
proteinuria? At first consideration, an increase in GBM
thickness might be expected to reduce protein transit.
However, careful analysis shows that the GBM thickening
occurs in an irregular manner with areas of thinned GBM.
Possibly more importantly, the GBM structural changes may
affect the adjacent cellular elements, reducing cell binding
and promoting cellular (in particular, podocyte) detachment.
PODOCYTES: THE FINAL FRONTIER TO PROTEINURIA
Although the mesangial cell has been considered to be at the
epicenter of injury in DKD, there is an increasing and
convincing body of research in the past few years document-
ing that injury to podocytes leads directly to proteinuria/
albuminuria in diabetic nephropathy.9,121 Moreover, injury to
podocytes also underlies progressive glomerulosclerosis in
diabetic nephropathy, and, thus, a decline in GFR.
A size and charge barrier
The third component to the glomerular filtration barrier,
considered by many to be the most important, is the
podocyte (Figure 2b). These are terminally differentiated cells
lining the outer aspect of the capillary loops in a very
complex architecture of interdigitating foot processes.122
Podocytes serve several important functions including
synthesis and perhaps maintenance of the underlying GBM,
counteraction of capillary hydrostatic pressure, and as a
critical member of the filtration barrier. The latter probably is
the most important function with regard to proteinuria and
some consider the podocyte to be the ‘last frontier’ protecting
against protein/albumin loss into the urinary space.
Structurally, podocytes have a cell body, from which
primary and secondary foot processes arise. These foot
processes are interdigitating and the narrow gaps (30–40 nm)
between neighboring processes are bridged by the glomerular
slit diaphragm. The slit diaphragm is a highly specialized gap
junction with small pores, permeable to water and solutes but
relatively impermeable to plasma proteins. The unique and
specialized shape of podocytes is supported by an actin
cytoskeleton, which not only serves a static function but
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which also allows the podocyte to continuously and
dynamically alter shape. Podocytes are anchored to the
GBM by integrins (predominantly the a3b1 integrin) and
a- and b-dystroglycans.
How do podocytes normally prevent proteinuria? Similar
to glomerular endothelial cells and GBM, podocytes are also
negatively charged on their apical membrane domain owing
to surface anionic proteins such as podocalyxin, podoplanin,
and podoendin. The negative charge helps limit passage of
negatively charged molecules (like albumin). However,
podocytes also serve as a size barrier to proteinuria,
predominantly due to the properties of the slit diaphragm.
The changes in size and charge properties of podocytes
occurring in DKD will now be discussed in detail in the
context of their contribution to the development and
magnitude of proteinuria.
Decreased podocyte number (podocytopenia)
Podocytes, like most cells, require a critical number to
perform their normal functions. Although adjacent podo-
cytes and their foot processes overlap to some extent, they
essentially are a monolayer of cells on the urinary side of the
GBM. Thus, one can easily envisage that if there is a focal area
(or areas) in the glomerulus where podocyte number is
reduced from whatever cause (these are discussed below), this
would create a specific area of vulnerability when it comes to
preventing protein loss (Figure 4). Reduced podocyte
number leads to proteinuria by the following mechanisms:
(i) an overall loss of negative charge, due to an overall
decrease in podocalyxin protein available to serve as a charge
barrier; (ii) disruption of the normal architecture of the
podocyte monolayer. As such, slit diaphragm integrity and
cell–cell connections are altered, and over time, ‘gaps’ are
noted in areas of reduced podocyte number. This leads to the
inability of podocytes to function as a size barrier, leading to
the unimpeded passage of protein and other molecules into
the urine. In addition to proteinuria, the reduced podocyte
number may fail to mechanically support the glomerular
capillary loop and may lead directly to glomerulosclerosis
and loss of renal function.123
What is the evidence for reduced podocyte number in
diabetics? A decrease in podocyte number has been shown in
patients with both type I and type II diabetes mellitus.124–127
Although podocyte number may be normal at early stages,127
in some instances, reduced podocyte number precedes the
onset of clinically detectable albuminuria and/or proteinuria
by several years.124 A European study suggests that podocyte
density, rather than podocyte number, may be more
predictive of albuminuria.128 Experimental and clinical
studies have also shown a direct correlation between the
extent of the decrease in podocyte number and the
magnitude of proteinuria.
Disruption of
slit diaphragm
Widening and effacement
of foot processes
Podocyte
apoptosis
3.
2.
Podocyte
detachment
Podocyte
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cell
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Podocyte
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endothelial cell
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Figure 4 | Podocyte abnormalities in DKD. (a) Normal podocyte architecture. (b) Some podocytes undergo apoptosis, resulting in reduced
cell number. Albumin can then leak through areas denuded of podocytes. (c) The normal architecture of the slit diaphragm is disrupted
(by either reduced levels of specific proteins and/or relocalization of these proteins) leading to a loss of size barrier. Podocytes also
undergo changes in shape due to effacement. (d) The normal function of podocytes is also limited by individual cells increasing in
size (hypertrophy) and detachment leads to reduced overall podocyte number.
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Causes of reduced podocyte number
The causes of reduced podocyte number in diabetic
nephropathy are multifactorial, and an active area of study.
These will be discussed below.
(i) Podocyte detachment (Figure 4d): There is substantial
evidence documenting podocyte detachment with
their subsequent appearance in the urine described as
podocyturia.129–131 One study described podocy-
turia in 53% of microalbuminuric and 80% of
macroalbuminuric type II diabetics, but was absent
in those with normal albumin excretion.132 Moreover,
many of these cells were viable podocytes, suggesting a
primary problem with their ability to stay attached to
the underlying GBM. Reduced expression of the a3b1
integrin, the predominant integrin tethering the
podocyte to the underlying GBM, appears to con-
tribute to podocyte detachment.133 The authors
speculate that the substantial changes in GBM
architecture in diabetes might also pose an unfavorable
‘footing’ to which podocytes attach, thus favoring
detachment.
(ii) Podocyte apoptosis (Figure 4b): Apoptosis (pro-
grammed cell death) of podocytes may be another
important cause of podocytopenia in diabetes and
has been shown to coincide with the onset of
albuminuria.134 Apoptosis has been difficult to docu-
ment in all podocyte diseases with the current
techniques that are available as the cells slough off
into the urine. For cells to undergo apoptosis, the
normal balance of pro-survival vs pro-apoptotic
signals is tipped. Although several mechanisms might
underlie apoptosis in diabetes, oxidative stress has
been implicated as an important and even potentially
treatable cause.134
(iii) Inability to proliferate and restore podocyte number:
Podocytes are terminally differentiated cells and thus
typically do not proliferate in vivo. Under normal
(unstressed and nondiseased) states, this poses no
threat. However, in the setting of loss such as
detachment or apoptosis, the relative inability of these
cells to proliferate and ‘replace’ their neighbors leads
to an eventual decline in number. Thus, relative lack of
appropriate podocyte replication may be another
contributing factor to reduced podocyte number in
diabetes. Studies have shown that alterations in
specific cell-cycle regulatory proteins might prevent
podocyte proliferation (reviewed in Shankland).135
Candidates include an increase in expression and
action of the cyclin-dependent kinase inhibitors p21
and p27, which prevent cell-cycle progression.136
Moreover, there may also be a change in the cell
phenotype in diabetes, where rather than proliferating,
podocytes undergo hypertrophy. This causes an
increase in cell size (not an increase in cell number).
How this maladaptive response contributes to protei-
nuria is not well defined.
Slit diaphragm abnormalities
As stated earlier, the major size barrier to the passage of
proteins and other macromolecules is the slit diaphragm
(Figures 2b and 4c). This has been extensively reviewed
elsewhere.137–139 In brief, the ‘gaps’ between adjacent foot
processes are bridged by highly specialized and specific
proteins, which form an intricate network such that pores
form that are slightly smaller than the size of albumin, thus
serving as a size barrier. Moreover, proteins of the slit
diaphragm are not only simply structural, but also function
to signal to other proteins within the body of the podocyte.
For example, nephrin, CD2AP, and podocin also serve a
survival function for podocytes. One can, thus, readily
appreciate how alterations in the structure and/or function of
these proteins lead to not only abnormalities in the size
barrier, but also to the overall integrity of podocytes.
A critical component of the glomerular slit diaphragm is
nephrin, with an expression pattern restricted to podocytes in
the kidney. Any alterations in levels or molecular makeup of
nephrin directly lead to podocyte abnormalities by limiting
the normal size barrier properties, by augmenting apoptosis,
and by altered cytoskeletal functions. Nephrin is shed into the
urine of diabetic patients with micro- and macroalbuminur-
ia,140 and nephrin staining is decreased in both patients with
type I and type II diabetes mellitus, correlating with
broadening of the foot processes.141–143 Interestingly, nephrin
has recently been shown to be also essential for vesicular
docking and insulin responsiveness of podocytes.144 Insulin
responsiveness may be important to enable a physiological
response in terms of allowing podocytes to rapidly metabo-
lize glucose to facilitate structural remodeling required to
respond to changes in filtration pressure.
Foot process widening and effacement
Foot process widening is found at early stages of diabetic
nephropathy and results in a decrease in the number of slit
pores per unit length of GBM.145 Foot process width has been
shown to correlate with the extent of albuminuria,146 and,
importantly, may be prevented by RAS blockade.147 This
raises the question of how might foot process widening
contribute to albuminuria? First, changes in the slit
diaphragm morphology may simply change the shape of
the size barrier, thereby allowing albumin/protein to make
their way into the urinary space. The decrease in slit
diaphragm length associated with widened foot processes
may impede the filtration of water and lower GFR. If at the
same time protein permeability remains unchanged, then the
amount of protein relative to water would increase in the
urinary space and the increased protein concentration may
exceed the reabsorptive capacity of the tubular epithelial cells
leading to proteinuria.148
Effacement or simplification of podocyte foot processes is
an active process with the retraction of the foot processes into
the cell body resulting in large areas of flattened epithelium
covering the capillary loop (Figures 3e and 4c). The exact
molecular mechanisms resulting in effacement remain
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unclear, although proposed mechanisms include disruption
of the podocyte actin cytoskeleton,149,150 loss of slit
diaphragms,151 or impairment of the podocyte–GBM inter-
action.152,153 It is not clear, however, that foot process
effacement alone can explain proteinuria, and indeed may be
simply a consequence of podocyte injury. The podocyte
flattening covers wide expanses of the GBM and the total area
for ultrafiltration is probably much decreased, although focal
epithelial defects may allow increased protein flux across
these denuded areas. It should be noted that there are several
experimental models where proteinuria occurs in the absence
of foot process effacement,154–158 and, similarly, effacement
can occur in the absence of proteinuria.159
Cytoskeletal changes in podocytes
(i) Altered cytoskeleton: There is recent evidence for
cytoskeletal changes of podocytes in diabetes. For
example, high glucose and advanced glycosylation end
products decrease the expression of a-actinin-4.160
Since a-actinin plays an important role in glomerular
filtration as a key molecule of the podocyte cytoske-
leton, reduced expression may contribute to protei-
nuria. For example, a reduction in a-actinin has been
shown to precede podocyte foot process effacement
and proteinuria in an experimental model of nephritic
syndrome.150
(ii) Reduced negative charge function: Loss of negative
charge on podocyte may be another mechanism in the
development of proteinuria in diabetes. Normally,
podocytes are covered with a negatively charged
glycocalyx consisting of sialoglycoproteins including
podocalyxin and podoendin. Recent experimental
studies have shown a decrease in podocalyxin expres-
sion in podocytes in response to high glucose.161 The
resulting loss in negative charge would make it easier
for negatively charged albumin to escape into the
urinary space.
In summary, there are a number of podocyte-specific changes
that occur in DKD, that likely are very important events in
the development and persistence of albuminuria and
proteinuria. These include a decrease in podocyte number/
density, widening of the foot processes, shortening of the slit
diaphragm/loss of slit diaphragm proteins, changes in actin
cytoskeleton, and decrease in negative charge. The mediators
and factors likely responsible for the abovementioned
podocyte changes in diabetes mellitus will be discussed
below.
THE MESANGIAL CELL: A LESSER ROLE IN THE PROTEINURIA
Reduced GFR and mesangial cells
Mesangial expansion and the development of the Kimmel-
stiel–Wilson lesion are perhaps the best known histological
characteristics of DKD (Figure 3). Indeed, for many years, it
was thought that changes in mesangial cells were central to
the clinical findings of DKD. These changes include (i) an
increase in mesangial cell size due to hypertrophy (not due to
increased cell number), and (ii) an increase in the
extracellular components due to an increase in a variety of
extracellular matrix proteins. Studies estimate that the
cellular component accounts for one-third of the mesangial
expansion, and the extracellular component the remaining
two-thirds. The mechanisms accounting for these mesangial
changes are summarized in several elegant reviews.8,162,163
The increase in cellular and extracellular mesangial compo-
nents correlates with, and likely causes, a decrease in GFR by
encroaching upon neighboring capillary loops, and with
time, reducing the capillary surface area for filtration.164,165
Although mesangial expansion clearly leads to a reduced
GFR, one is left asking does mesangial expansion also cause
proteinuria. It is the view of the authors that mesangial
expansion per se is not sufficient to cause proteinuria directly
based on several lines of evidence. First, mesangial expansion
is an early change in DKD and begins prior to the onset of
albuminuria.115 Second, DKD is described both in animal
models (Cohen rat)166 and in humans,4,28,167 in the absence
of proteinuria, but in whom prominent mesangial expansion
is noted on biopsy. Notably, the Cohen rat does not seem to
pass through an early hyperfiltration phase, and, therefore,
glomerular hypertension and accompanying podocyte injury
may not develop.
The authors believe that mesangial injury rather leads to
secondary changes in the filtration barrier, which then results
in proteinuria. First, DKD may be associated with mesan-
giolysis leading to the development of microaneurysms and
endothelial cell injury. Second, we would also speculate that
with the anatomic disruption in the capillary loops from
microaneurysmal dilatation that there is increased stress–
tension generated on podocytes. The analogy would be that
of a balloon (capillary loop) being inflated. With increasing
distention of the balloon, there is increasing tension on the
walls, and a critical pressure leads to disintegration. Third,
pioneering work by Brenner and colleagues showed that
reduced nephron mass causes increased intraglomerular
capillary pressure in the remaining nephrons. We would
therefore argue that as glomeruli undergo increasing
sclerosis, in large part due to the accumulation of mesangial
extracellular matrix proteins in DKD, other less affected
glomeruli (or less affected loops of a single glomerulus)
experience increased glomerular pressure. Thus, glomerular
hypertension will lead to podocyte injury (with proteinuria),
and, subsequently, focal glomerulosclerosis and renal dys-
function. Taken together, while mesangial expansion in DKD
clearly reduces GFR, it is unlikely to directly cause
proteinuria, but may do so indirectly by generating
glomerular hyperfiltration.
TUBULOINTERSTITIAL INJURY: AN OVERLOOKED
CONTRIBUTOR TO PROTEINURIA
As discussed earlier, there are often substantial tubulointer-
stitial changes seen on renal biopsy in diabetics, and it is well
established that tubulointerstitial scarring is perhaps the best
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predictor of renal survival in both diabetic and nondiabetic
disease.168,169 The reader is referred to excellent reviews on
the causes of tubulointerstitial injury in disease, and how this
reduces kidney function.170,171 How might tubulointerstitial
injury itself either cause proteinuria, or augment proteinuria
that is primarily due to abnormalities in the glomerular
filtration barrier? We can appreciate that interruption of this
protein reabsorption process in the proximal tubule may lead
to proteinuria, although interstitial injury per se, without an
increase in glomerular protein filtration, would not be
expected to cause nephrotic range proteinuria. Of note, an
alternative view suggests that, even with normal glomerular
function, there are very large amounts of albumin filtered at
the glomerulus and that protein retrieval in the proximal
tubule is a high volume process and a prime regulator of
urine protein excretion.15 In this model, classic glomerular
diseases are associated with proximal tubular injury leading
to reduced proximal reabsorption of albumin, and, as a
result, the development of nephrotic range proteinuria. We
believe that tubulointerstitial injury augments urine protein
excretion by impairing the reabsorption of filtered (glomer-
ular) protein. Although not definitive, the bulk of the data
would suggest that 4–5 g of albumin are filtered at the normal
glomerulus each day.16–18 In diabetes, proximal tubular
reuptake of protein may be impaired by high glucose,172
TGF-b,173 or angiotensin II.174 With the development of
glomerular disease, tubulointerstitial injury is enhanced and
the ability to reabsorb protein is further reduced. The
increased ‘glomerular’ proteinuria can easily overwhelm the
capacity of injured tubular cells to reabsorb the filtered
protein load. Taken together, the magnitude of proteinuria is
now markedly increased due to this ‘compounding’ effect of
both glomerular and tubulointerstitial injury. Of note, there
is a direct correlation between the degree of tubulointerstitial
scarring and the extent of albuminuria,175 and it is likely that
each of these variables serves to amplify the other.
CONCLUSION
Proteinuria (increased urinary albumin excretion) in patients
with diabetes is a signature feature of DKD. Although
progressive renal impairment due to glomerular and
tubulointerstitial scarring has been described in the absence
of proteinuria, the two typically occur together. The
mechanisms underlying proteinuria, and glomerular and
tubulointerstitial fibrosis may overlap in part. Proteinuria in
DKD is predominantly due to disturbances in the glomerular
filtration barrier, consisting of the glomerular endothelial cell,
the GBM, and the podocyte. Although it is tempting to
identify the podocyte as perhaps the predominant compo-
nent of this barrier, it is becoming clear that each layer of
resistance within the filtration barrier contributes uniquely to
the overall permselectivity preventing proteinuria. Thus,
injury to one or more layer in DKD results in the onset of
proteinuria, and persistent proteinuria may result from either
a lack of adequate repair and/or injury to further compo-
nents of the filtration barrier. Tubulointerstitial injury may
also contribute to proteinuria by impairing proximal tubular
protein reabsorption. Proteinuria, along with other factors,
may lead to progressive glomerulosclerosis and tubulointer-
stitial fibrosis, with a subsequent decline in GFR (Figure 1).
The studies highlighted in this review provide hope to our
patients that extensive efforts are underway aimed at
uncovering the mechanisms underlying proteinuria in DKD
so that specific therapies can be developed to reduce the
burden of kidney and cardiovascular disease.
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